compugen

FROM CODE TO CURE®



Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update

October 2026

Safe Harbor Statement

This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” and “intends,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including statements regarding the timing and success of our clinical trials, enrollment of patients, type of clinical trials, presentation of data and our cash position and expenditures. Among these risks: Clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product, or may not be able to conduct or complete its trials on the timelines it expects; Compugen relies and expects to continue to rely on third parties to conduct its clinical trials and these third parties may not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and Compugen may experience significant delays in the conduct of its clinical trials as well as significant increased expenditures; Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen’s approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (“SEC”) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law. Certain studies and data presented herein have been conducted for us by other entities as indicated where relevant. Intellectual property, including patents, copyrights or trade secret displayed in this presentation, whether registered or unregistered, are the intellectual property rights of Compugen. Compugen's name and logo and other Compugen product names, slogans and logos referenced in this presentation are trademarks of Compugen Ltd. and/or its subsidiary, registered in the U.S.A., EU member states and Israel.

Agenda

Virtual KOL Event | Monday, October 5, 2026 | 8:00 AM ET | Live Webcast

Topic	Presenter
Welcome & Introduction Compugen Overview MAIA-Ovarian: Randomized Adaptive Platform Trial of COM701 in Platinum Sensitive Ovarian Cancer *(Interim analysis expected by Q1 2027)*	**Eran Ophir, Ph.D.** *President & Chief Executive Officer of Compugen*
Evolving Treatment Landscape in Ovarian Cancer	**Oladapo Yeku, M.D., Ph.D., FACP** *Harvard Medical School; Massachusetts General Brigham*
Unigen™ Platform Update: Expanding pathways to discover first-in-class targets	**Sharon Kredo-Russo, Ph.D.** *Senior Vice President, Research & Discovery*
Question & Answer Session	**Dr. Yeku & Management Team**

Focus on novel immuno-oncology antibodies

Discovered by Compugen's computational discovery platform-Unigen™

Rich clinical pipeline with validating partnerships >$1bn in milestones PLUS royalties

Fully-owned Clinical Assets

COM701
Potential 1st in-class
Anti-PVRIG antibody

COM902
Fc-reduced anti-TIGIT antibody

Phase 3 AstraZeneca program

Rilvegostomig
AZ est. **>$5bn PYR[1]**
anti-PD1/TIGIT bispecific Ab,
TIGIT component derived
from COM902

AstraZeneca

Phase 1 licensed to Gilead

GS-0321 (previously COM503)[2]
Potential first-in-class
Anti-IL-18BP antibody

GILEAD

Early-stage pipeline

Multiple assets
in research undisclosed

Cash balance $125.3M
as of June 30, 2026

Expected cash runway into
2029 to support operations

COM701 MAIA-ovarian interim analysis projected by Q1 2027
Advancement of GS-0321 Phase 1 trial
Advancement early-stage pipeline

compugen
FROM CODE TO CURE®

1. PYR: AstraZeneca 's guidance from 2024 Investor Day for non-risk adjusted peak year revenue for rilvegostomig inclusive of all indications and excludes non-registrational trials
2. Compugen responsible for preclinical development and first- in-human Phase 1 trial evaluating the safety and tolerability of GS-0321. Thereafter, Gilead will have sole right to develop and commercialize GS-0321.

Strong biological rationale to target PVRIG in ovarian cancer

- High **PVRIG pathway** expression levels in **ovarian cancer**
- **PVRIG pathway** differentially expressed on early differentiated stem like memory T cells and dendritic cells compared to other immune checkpoints
- PVRIG blockade with **COM701** alters the tumor microenvironment including in less inflamed tumors **like ovarian cancer**



Alteber et al, Cancer Immunology Research, 2024

Characterizing PROC responding patients across Phase 1

Guided the design of ongoing MAIA-ovarian PSOC maintenance platform trial

Patients derived clinical benefit irrespective of PD-L1 status



Patients without liver metastases - more likely to derive clinical benefit



C1D1: Cycle 1 Day 1; CR: complete response; NA: not applicable; PD: progressive disease; POS: positive; PR: partial response; SD: stable disease.

CB: clinical benefit; W/O: without.

COM701 alone and in combination was well tolerated and demonstrated consistent, durable responses in heavily pre-treated PROC patients, particularly in patients without liver metastases, as well as patients who were PD-L1 negative

Data support advancing to a maintenance strategy in an earlier setting of ovarian cancer

Ongoing MAIA-ovarian platform trial is evaluating COM701 maintenance therapy in relapsed PSOC without liver metastases, for which there is a significant unmet need

compugen
FROM CODE TO CURE®

Advancing COM701 to address unmet need in PSOC

Building on data generated in PROC



Potential benefits of COM701:

- ✓ Longer time before progression
- ✓ Recovery break from chemotherapy
- ✓ Delay transition to PROC
- ✓ Preserve additional treatment options

compugen
FROM CODE TO CURE®

Confidential

MAIA-ovarian: adaptive trial with maintenance COM701 therapy in relapsed platinum sensitive ovarian cancer

Key eligibility criteria

Relapsed platinum sensitive ovarian cancer

Complete or partial response following platinum-based chemotherapy

Maintenance therapy post bevacizumab and/or PARP inhibitor or not a candidate for bevacizumab and/or PARP inhibitor

Presence of liver metastases excluded

Sub-trial 1
Single agent activity of COM701
versus placebo (standard of care)

Adaptive trial n= 60
2:1 Randomization

Sub-trial 2 and beyond
COM701 combination studies e.g.
anti-PD-1/TIGIT or bevacizumab or PARPi or others

Endpoints

Primary: Efficacy-median progression free survival

Secondary: Safety

Exploratory: Biomarkers

Timelines: sub-trial 1

Trial initiation: Q2 2025

First patient dosed: July 2025

Projected Interim analysis: Q1 2027

Evaluation of COM701 single agent activity, combinations and contribution of effects, represents a regulatory and commercial opportunity

compugen
FROM CODE TO CURE®

https://clinicaltrials.gov/study/NCT06888921?cond=COM701&rank=1

Mass General Brigham

Evolving Treatment Landscape in Ovarian Cancer

Oladapo Yeku, MD, PhD, FACP, FASCO
Associate Professor of Medicine, Harvard Medical School
Director of Translational Research
Center for Gynecologic Medical Oncology
Massachusetts General Hospital

October 5, 2026

A cycle of remission and relapse

1

Initial treatment

Surgery and chemotherapy. Most patients respond well.

2

Remission

Some continue on a maintenance drug. Many do not.

3

Relapse

Treatment resumes. Each remission tends to be shorter.

Time spent in remission — off chemotherapy — is what **patients and clinicians value most**

One interval shapes the next decision

Platinum Free Interval (PFI): Time from the last platinum chemotherapy until the cancer returns

Sensitive	Resistant
PFI over 6 months	PFI under 6 months



Platinum sensitivity determines the next treatment and informs prognosis

THE GAP

Patients in remission with no treatment options

Who they are

- Responded to their most recent chemotherapy
- Ineligible for, or have exhausted, maintenance options
- Still recovering from cumulative toxicity
- Seeking a chemo-free interval

Current practice

Observation

Periodic scans, with treatment resuming only at relapse.

Why the setting is attractive for study

A defined population, no approved option, and a placebo comparator that reflects real standard of care.

The maintenance challenge remains

- 1st line usage of PARPi and Bev leaves more 2nd and 3rd line patients without maintenance options
- ADCs are reshaping treatment, but maintenance still requires tolerable regimens

01 MOMENTUM

ADCs moving into platinum-sensitive disease

02 PAYLOAD CONVERGENCE

Most programs cluster around Topo-1 payloads

03 MAINTENANCE FIT

Prolonged tolerability is not easy for every patient

Three reasons the setting was selected

1

A distinct immune pathway

COM701 acts on a novel checkpoint where previous checkpoint inhibitors have failed

2

Early clinical observations

Across early CGEN PROC trials in 60 heavily pre-treated patients: durable responses and good tolerability

3

Favorable conditions

Less compromised immune system in earlier lines of therapy and low tumor burden

Tolerability determines whether patients will accept months of continued treatment

UNMET MEDICAL NEED

COM701 as a potential maintenance option

2nd/3rd Line Maintenance Therapy in Platinum Sensitive Ovarian Cancer

GOAL

Extend the duration of platinum sensitivity for patients in remission with no approved maintenance option.

Potential for:

- **Maintaining platinum sensitivity**
- **Extending the remission interval**
- **Chemotherapy sparing regimen**

Investigational agent; not approved by FDA

Questions

compugen

FROM CODE TO CURE®

From a Validated Discovery Engine to New Opportunities



Dr. Sharon Kredo-Russo, SVP Research & Discovery

October 2026

A Rich Clinical Pipeline. Global Pharma Partnerships

Early-stage pipeline	Fully-owned Clinical Assets	Phase 1 licensed to Gilead	Phase 3 AstraZeneca program
Multiple assets	**COM701** **COM902**	**GS-0321** (previously COM503) [1] GILEAD	**Rilvegostomig** AstraZeneca

1. Compugen responsible for preclinical development and first- in-human Phase 1 trial evaluating the safety and tolerability of GS-0321. Thereafter, Gilead will have sole right to develop and commercialize GS-0321.

Behind the Discoveries: unigen™ by compugen

Compugen's proven AI-powered discovery engine, continuously connecting computational prediction, biological validation and clinical learning.



Expanding Compugen's Target Discovery into Tumor-Associated Antigens (TAAs)

TAAs provide the tumor address for targeted therapies, directing immune activity or drug delivery toward cancer cells





T-cell Engagers (TCEs)

Bring T cells into direct contact with tumor cells, triggering anti-tumor activity.



Targeted Immune Activation

Engage other immune cells or activate immune pathways (e.g., cytokines, co-stimulation) through tumor-selective targets.



Additional Targeted Modalities

TAA-directed therapies beyond immune engagers, including antibody-drug conjugates (ADCs).

Large unmet need in targeted therapies- novel selective TAAs

compugen
FROM CODE TO CURE®

T-cell Engagers Create an Immediate Need for the Right Tumor Targets

A Powerful Modality

TCEs trigger potent anti-tumor activity, with growing potential in solid tumors

TAAs Direct the Activity

TCEs rely on TAAs to direct T-cell activity toward tumor cells, making target selection critical to efficacy and safety



T-cell Engager (TCE)

Growing Market Opportunity

>$18–20B

projected market by 2035*

Few TAAs Have the Right Profile

The right TAAs combine tumor specificity, low normal-tissue exposure, and high tumor cell coverage

*Source: Custommarketinsights report T-cell engager market size

A Powerful Therapy Is Only as Good as Its Target

12 T-cell engager drugs have been approved, validating the therapeutic modality, yet only 2 in solid tumors, where target quality remains a critical constraint

Mesothelin-directed TCE*

High normal-tissue expression (lung)

Dose-limiting on-target off-tumor toxicity

Development discontinued

Clean profile
Tarlatamab - APPROVED



*ZW171 example

compugen
FROM CODE TO CURE®

compugen
FROM CODE TO CURE®

unigenX™
by compugen

Expanding Compugen's proven discovery engine in IO to uncover novel TAAs



unigenX™ by compugen AI-Powered Discovery Engine, Built for TAAs

Compugen's validated AI-powered discovery engine, continuously connecting computational prediction, biological validation and clinical learning



unigenX™ by compugen Finding the Right TAAs

Unique multi-omics approach



Versatile discovery platform
Adapting AI-driven discovery and analysis to each biological challenge

Deep biological understanding
Revealing insights across biological layers that no single view can provide

Novel target discovery
Uncovering novel targets with the goal of translating them into clinical-stage therapeutics

unigenX™ by compugen Search Broadly, Understand Deeply

Search Broadly

A rich biological landscape for discovery

> 100M
Single cells

> 50K
Samples across >1000 IO datasets

>3,700
Tumor & normal proteomic samples

21
Cancer subtypes

42
Normal-tissue scRNA atlas spanning >150 cell types



Understand Deeply

A multidimensional target profile

Tumor specificity

Patient population coverage

Intratumoral heterogeneity

Safety – Normal tissue exposure

Therapeutic index

From Biological Evidence to Informed TAA Selection

Integrating multiple biological layers into explainable, multidimensional target scores

Predicted Safety and Efficacy Profiles
Colorectal cancer



Transparent
scoring system



unigenX™ by compugen **Identify targets with potential better profile than benchmarks**

Multi-Omics Evidence Supports Differentiated TAA Candidates

Safety- Healthy and cancer tissue Expression



Tumor- Cell-type specificity & coverage





Protein confirmation



IHC Maps tissue localization & tumor specificity [1]



Converging evidence builds confidence in the target differentiated biological profile

Candidates prioritized for further experimental validation

1. Representative IHC image of target Z

Target Pairs Expand the TAA Discovery Opportunity

Some therapeutic challenges may be addressed more effectively through paired-target approaches

AND Gating

Sparing the healthy cells



OR Gating

Broaden tumor coverage



compugen
FROM CODE TO CURE®

Target Pairs Expand the TAA Discovery Opportunity

AND Gating

Improve tumor selectivity- example from colorectal cancer



OR Gating

Broaden tumor coverage- example from prostate cancer



unigenX™ by compugen expands TAA discovery from individual targets to complementary target combinations

One Discovery Engine, Broader IO Opportunities



A validated foundation

unigen™ by compugen

Novel IO Target Discovery

Discovering previously unrecognized IO targets and translating them into clinical-stage therapeutics and global pharma partnerships



Expanding into a new high-value frontier

unigenX™ by compugen

Novel Target Discovery in Targeted Immune Activation

Expanding Compugen's proven discovery engine into novel TAA discovery with the goal to create differentiated opportunities for various modalities

Potential: Novel TAAs · TAA pairs · TCE opportunities

unigenX™ by compugen Multiple Potential Paths to Value



Discovery of multiple assets

Novel TAA-driven therapeutics across solid-tumor indications



Enable partnerships

Collaborations across discovery and development



Leverage of internal pipeline

Potential combinations with Compugen's current programs

compugen

FROM CODE TO CURE®

Validated Discovery Engine. Expanded Possibilities.

Compugen expands its validated discovery engine through UnigenX™, creating complementary opportunities across immuno-oncology.



Thank you

www.cgen.com